chrisvoncsefalvay/vaers-outcomes huggingface dataset:
ran a fever of 101.9 Fahrenheit; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (ran a fever of 101.9 Fahrenheit) in an 81-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 034F21A, 024M20A and 016M20A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concurrent medical conditions included Asthma and Drug allergy (she has a lot of allergies to prescription medications but did not list the names of the medications). Concomitant products included ROSUVASTATIN, HYDROCHLOROTHIAZIDE (HCTZ), SPIRONOLACTONE, COLECALCIFEROL (VITAMIN D3) and MULTIVITAMINS [VITAMINS NOS] for an unknown indication.   On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 23-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 23-Nov-2021, the patient experienced PYREXIA (ran a fever of 101.9 Fahrenheit). The patient was treated with PARACETAMOL (TYLENOL [PARACETAMOL]) for Adverse event, at an unspecified dose and frequency. On 26-Nov-2021, PYREXIA (ran a fever of 101.9 Fahrenheit) had resolved.            This case was linked to MOD-2022-438683, MOD-2022-438642 (Patient Link).
Initial information received on 20-Sep-2018 regarding an unsolicited valid non-serious case received from a Nurse. This case involves a five-years old female patient who experienced localized reaction of large swelling, while she received vaccine FLUZONE QUADRIVALENT. The patients past medical history, concomitant medication and family history were not provided. On an unknown date in 2015, the patient received a 0.5ml dose of suspect INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED lot UI440AD, expiry date 30-Jun-2016 via intramuscular route in the deltoid NOS. On an unknown date, patient developed a non-serious localized reaction of large swelling with unknown latency following the administration of FLUZONE QUADRIVALENT. For this reason, the flu vaccine was omitted for the patient in 2016. It was reported as in 2017, at a different site not affiliated with this case, patient received another flu vaccination (unknown Brand) in the thigh and the father reports another localized reaction (football sized). Relevant tests were not reported. Final diagnosis was localized reaction of large swelling. It was not reported if the patient received a corrective treatment. On an unknown date the patient was recovered from the event. Documents held by sender- none.
Did not feel well after root canal; Psoriasis worse; Did not feel well after root canal; This spontaneous case was reported by a consumer and describes the occurrence of ENDODONTIC PROCEDURE (Did not feel well after root canal), PSORIASIS (Psoriasis worse) and MALAISE (Did not feel well after root canal) in an elderly female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) for Psoriasis.    No Medical History information was reported.   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) (Subcutaneous) 1.785 milligram. On an unknown date, the patient experienced ENDODONTIC PROCEDURE (Did not feel well after root canal), PSORIASIS (Psoriasis worse) and MALAISE (Did not feel well after root canal). At the time of the report, ENDODONTIC PROCEDURE (Did not feel well after root canal), PSORIASIS (Psoriasis worse) and MALAISE (Did not feel well after root canal) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.  The patient's psoriasis had worsened after she had taken Moderna vaccine for COVID and did not feel well after a recent root canal.  It was unknown if patient was enrolled in a COVID-19 vaccine trial.   The reporter's causality with Skyrizi for the events of did not feel well after root canal  and psoriasis worse was not provided.  No treatment information was provided.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.   Most recent FOLLOW-UP information incorporated above includes: On 21-Jan-2022: Additional follow up received event information was updated.
no symptoms or side effects  reported even 2nd dose was administered couple of days early as family had to leave for out of town due to an emergency
This spontaneous case was reported by a consumer and describes the occurrence of BACK PAIN (Severe low back pain), MYALGIA (Couldn't get out of bed because of back pain) and PAIN (Back hurting so bad) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013M20A and 025J20A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure. Concomitant products included ACETYLSALICYLIC ACID (ASPRIN), ATORVASTATIN CALCIUM (LIPITOR ORIFARM) and ESCITALOPRAM OXALATE (LEXAPRO) for an unknown indication.   On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 24-Feb-2021, the patient experienced BACK PAIN (Severe low back pain), MYALGIA (Couldn't get out of bed because of back pain) and PAIN (Back hurting so bad). The patient was treated with PREDNISONE at an unspecified dose and frequency. At the time of the report, BACK PAIN (Severe low back pain), MYALGIA (Couldn't get out of bed because of back pain) and PAIN (Back hurting so bad) had not resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
This spontaneous report as received from a physician refers to a patient of unknown age. On 05-AUG-2013 the patient was vaccinated with a dose of PNEUMOVAX 23 (lot # H012650, expiration date: 27-FEB-2014) (dose, route unknown) which was improperly stored. No adverse event reported. This is one of several reports (1403USA001193; 1403USA001194; 1403USA001195) from the same reporter. Additonal information is not expected.
hx of genital herpes; pt recvd flu vax & precipitated an outbreak;
Patient arm swelled from shoulder to elbow, very sore and hot to touch. Patient received vaccine 11/5/18 in am and swelling was present by evening.
Influenza Vaccine given 9/29/03. Client presents 10/6/03 with reddened purple non-tender nodules. .25-1.0 cm areas on palms and dorsum of hands and back. Client indicates it started 1 week prior. Physician indicates "probable erythem nodosum to flu vaccine. Gave Methylpred 60mg IM X1. Triamcinolone topical. Rash faded 10/14/03.
CLIENT WAS GIVEN THE WRONG DOSE. INSTEAD OF A 2ND MONOVALENT VACCINE, THE CLIENT RECIEVED A BIVALENT DOSE.
Dizziness; nausea; headache; constant eye and nose drain; constant eye and nose drain; burning eye and nose; burning eye and nose; weakness; tiredness; sore lips and throat; sore lips and throat; sore on tongue; chest tightness; This is a spontaneous report from a contactable consumer reporting for herself.  A 62-year-old female patient received the 1st dose of bnt162b2 (BNT162B2) at single dose at left arm on 14Jan2021 11:30 for Covid-19 immunisation, administered at hospital.  Medical history included hypertension, high cholesterol, diabetes mellitus, allergies penicillin. Patient was not pregnant at the time of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medication within 2 weeks of vaccination included atenolol (manufacturer unknown), losartan (manufacturer unknown), atorvastatin (manufacturer unknown), hydrochlorothiazid (manufacturer unknown). The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 15Jan2021 07:00 the patient experienced dizziness, nausea, headache, constant eye and nose drain, burning eye and nose, weakness, tiredness, sore lips and throat, sore on tongue, chest tightness. The patient underwent lab tests and procedures which included Sars-cov-2 nasal swab test: negative on 19Jan2021. The outcome of all events was not recovered as all ongoing now for 1 week. The events were considered non serious.  Information on the lot/batch number has been requested.
excessive somnolence beginning w/in 2hr p/vax given persisting x24hr;
At 02:55 PM Co Lead RN was alerted by vaccinator LVN that she had an incident with a client. Client came in today 12/05/2021 for Moderna COVID-19 vaccine booster dose lot# 035C21A. Vaccinating LVN showed Co Lead RN the empty syringe full of air. Vaccinating LVN stated, "I began to administer the vaccine into the client's right deltoid and as I was about to push the plunger I then saw that the syringe was full of air with no vaccine dose in it. I recapped the needle to show you and I told the patient the situation." Co Lead RN witnessed the syringe and saw it capped with only air. Co Lead RN confirmed with Vaccinating LVN and with client that zero vaccine was administered into her right deltoid. Client denied pain at the injection site. Co lead RN then reeducated client that since administration was below 50% that per CDC guidelines it would be necessary to pursue re-administering the vaccine immediately. Co lead PHN and LVN received verbal consent from client to re-vaccinate with Moderna COVID-19 booster. Client did not want to switch to left deltoid and wanted vaccine in right deltoid. At 02:58 PM, vaccinating LVN administered Moderna COVID-19 vaccine booster dose lot# 035C21A into right deltoid 1 inch away from previous injection site. Client completed 15 minute observation with no incident. Client was seen leaving vaccination site with steady gait.
Patient returned to pharmacy where she had been vaccinated 2 days prior. She said that on that night & for the last 2 days she was experiencing a large, swollen, hard welt at the injection site and her arm was painful even when not touched. Did consult her that it was most likely an injection site adverse reaction, and if the pain & swelling persisted to contact PCP.
Pt rec'd vaccine, 1st dose, afternoon, Friday next after noon, noted nausea, no vomiting, chills, headache, fever (not recorded), and generalized weakness on 2/1. Pt was better by the next day 2/2 though symptoms were on and off. By 2/2, was at work, able to function, without sequela.
Around 7:30pm the evening of 10/01/23 a large fevered welt type place started to develop. At this point it was roughly the size of a quarter. On 10/02/23 around 8:39 pm (times are confirmed with images I took of place on arm) it became a deep red and just about quadrupled in size. On top of this very painful place on my arm I was both freezing and in a cold sweat at the same time, felt like I was going to puke, had a fever, and hurt all over. Currently on 10/03/23 at 11:03 pm it has grown more and became an even darker shade of red. It is still tender and warm to the touch.
EXPIRED VACCINE ADMINISTERED; This spontaneous report received from a health care professional concerned a 37 year old female. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 043A21A, expiry: 19-SEP-2021) dose was not reported, administered on SEP-2021 for prophylactic vaccination. No concomitant medications were reported. On SEP-2021, the patient experienced expired vaccine administered. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of expired vaccine administered was not reported. This report was non-serious. This case, from the same reporter is linked to 20210949302, 20210949996, 20210949974, 20210950004, 20210950006, 20210949322 and 20210949808.
On 5/27/00, the pt was seen in a clinic and was diagnosed with seizure and upper respiratory infection. The child partially recovered. On 6/2/00, the pt was placed on therapy with Carbamazepine. Both the investigator and the medical monitor agree that the epilepsy and the URI are not reasonable related to the Prevnar administration. The relationship of the seizure, epilepsy and URI to the MMR and Varicella is unknown. Epilepsy and seizure were considered to be an "other important medical event". Additional information has been requested.
Information has been received from a lawyer regarding a case in litigation concerning a male patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare providers recommended and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related injuries. In 2016, a healthcare provider administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). In 2016, the patient was treated by a healthcare provider for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Additional information has been requested.
pt recv vax & fever 103 3PM which lasted till 7AM next day;pt sleepy all the time, hard to wake up;pt taken to ER 10PM given motrin which relieved fever for 2 1/2hr;pt was shaking or shivering for about 4hr prior to being seen;swollen leg;
1/27/20 at 0545 Patient presented to ED with rash concerning for Varicella, first noticed on this date. He has a history of B ALL. He received chemo on 1/27/20 at 1100. Completed Cytarabine on 1/26/20, takes Thioguanine daily ordered 1/23/20-2/6/20. He was noted to have small clusters of erythematous vesicular papules on left forearm, left upper arm, left trunk and left back. Fever T max 99.5.  Treatment: admitted to Hospital. started on Acyclovir 500mg/m2/dose Q 8 hr. Follow up lesion and blood testing. Concerns for VZV being wild-type or vaccine strain re-activation given immunocompromised state. Sent to CDC for strain testing. Continued Acyclovir until 2/6/20 (date of last chemo).   Patient admitted on 1/27/20 to hospital. Patient discharged on 2/7/20. Patient?s mother reports he?s doing well since discharge per a progress note from MD on 2/13/20. Patient has not had any new lesions and current lesions are healing.
Patient hospitalized for  forceps-assisted vaginal delivery. Following delivery, the patient had an uncomplicated postpartum course. No information given on baby. This was within 6 weeks of receiving covid vaccination.
On 9/5/16 beginning at 2 pm patient was unable to walk and experienced a fever, headache, tiredness, muffled hearing, nausea, vomiting, stomach ache, chills, sore joints, body aches, rash, dizziness, weakness, fever blister. The following day she experienced diarrhea.
Heartbeat started to bound; then my lips and tongue felt tingly for a couple minutes; then the symptoms faded away. Back of throat felt hot, but not swollen.
He tested positive last Tuesday for SARS-Cov-2; He tested positive last Tuesday for SARS-Cov-2; This is a spontaneous report from a Pfizer Sponsored Program, Pfizer First Connect via a contactable other health professional (HCP) (patient). A male patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 18Dec2020 at single dose for covid-19 immunization.  The patient medical history and concomitant medications were not reported. The patient tested positive last Tuesday (05Jan2021) for SARS-Cov-2 and the patient wanted to know if he could receive his second dose of vaccine. The outcome of the event was unknown.  Information on the lot/batch number has been requested.; Sender's Comments: Based on the information currently available, a lack of efficacy with the suspected vaccine BNT162B2 in this patient cannot be completely excluded. Further information like confirmative virus genome /nucleic acid detection is needed for meaningful medical assessment.
This spontaneous report as received from a pharmacist refers to a female patient of unknown age. The patient concurrent condition, medical history and concomitant medications were not reported. On 04-JUL-2017, the patient was vaccinated with M-M-R II for prophylaxis. Other suspect therapies included sterile diluent (MERCK STERILE DILUENT). On 22-JUL-2017, the patient started therapy with oral Keflex and ophthalmic Polycin ointment for an unknown reason (adverse event). The patient sought medical attention and consulted the Pharmacist. It was reported that the patient received unspecified treatment for the adverse event. The outcome of adverse event was unknown. The reporter did not provide the causality between the event and the suspect therapy. Additional information has been requested.
When I woke up the day after receiving the vaccine, the entire left side of my body was in pain. All the way from my arm, down to my ankle. I could hardly walk. In addition to this, I felt like I had the flu. Headache, fatigue, hot flashes, coughing. I vomited once in the evening. I received the vaccine on Friday, and Saturday was my worst day. I felt a bit better on Sunday, and back to normal on Monday.
Pt wanted to get the booster shot again after 3 series because she is immunosuppressant.  She didn't have her vaccine card and brought back her card later on. Because she is regular customer here and she never told us this would be the 4th dose.
Headache; Dizziness; Fatigue; Sore throat; Runny nose; Pain at injection site; Body Aches; Fever; Sweating; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955), via an unspecified route of administration in the arm left on 25Mar2021 at 16:00 (at the age of 35-years-old), as a single dose for COVID-19 immunisation. Medical history included high blood pressure, hypothyroidism and egg allergy.  The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021 at 00:00, the patient experienced headache, dizziness, fatigue, sore throat, runny nose, pain at injection site, body aches, fever and sweating. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient was treated for the headache, dizziness, fatigue, sore throat, runny nose, pain at injection site, body aches, fever and sweating with over the counter (OTC) medications. The clinical outcome of the events headache, dizziness, fatigue, sore throat, runny nose, pain at injection site, body aches, fever and sweating were not resolved at the time of reporting.   No follow-up attempts are needed. No further information is expected.
approx 1-2 hrs p/receiving Hep B vax pt devel pain down rt hand w/edema & tenderness @ site of inject; denies numbness & tingling; also c/o sharp pain down fifth finger of rt hand;
Substernal center chest tightness x3 days. Chest tightness with small intervals of pain that would increase when laying on side. Tightness and pain occurred with the first and second injections. Two other co-workers (same vaccine lot #) polled about their symptoms stated the same chest tightness and pain. Tightness described as the "need to belch but unable to".
Widespread erythma over entire body (except head). Rash was not raised or bumpy-looked like a severe sunburn. Edema and rash in both lower legs.
pain in R arm/bicep swollen lymph nodes over right clavicle, with redness and pain on palpation
Sore arm around injection site during the night.  Next day feeling achey and tired.  No fever or headache.  Symptoms gone by second day (3/17/21).
Information has been received from a lawyer regarding a case in litigation concerning a male patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare provider recommended and/or prescribed the ZOSTAVAX vaccine to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On an unknown date in 2012, a pharmacist at a pharmacy administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). On an unknown date in 2014, the patient was treated by a physician for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization (dates unknown), physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions (unspecified); lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Additional information has been requested.
Pt vaccinated with OPV during spring of 1965 developed paralysis of the vocal cord.
Information has been received from a registered nurse concerning a 30-year-old adult black female with an allergy to fish who on 10-NOV-2000 and 11-DEC-2000 was vaccinated with the first (SC in the right upper arm) and second (SC in the left upper arm) adult doses of Varivax (lot # 635204/0072K). There was no illness at the time of vaccination. In September 2006, the patient tested for seroconversion to varicella. Medical attention was sought. There was no product quality complaint involved. There were no other adverse events. No additional information is expected.
Patient was given the adult dose of the vaccine per provider discretion due to child's weight of almost 200 pounds and patient turns 12 on 1/26/22. Child did not have any adverse reaction to this vaccine. The wrong dose of the vaccine was given.
Tinnitus--loud high-pitched buzzing (sounds like a TV channel that doesn't get reception)
Syncope upon standing approx 5 mins after vaccine. Vomited c/o chills. Fluids, crackers given rested x 1 hour then left feeling better.